| dbo:abstract
|
- Etelcalcetid ist ein Arzneistoff zur Behandlung des sekundären Hyperparathyreoidismus, einer Erkrankung die vor allem bei Menschen mit einer Chronischen Nierenerkrankung auftritt und zu erhöhten Parathormon führt. (de)
- Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan. (en)
- L'ételcalcétide (ou velcacétide) est une molécule en cours de test comme médicament dans le traitement des hyperparathyroïdies secondaires. (fr)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 9703 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:date
| |
| dbp:eliminationHalfLife
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:index2Label
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalUs
| |
| dbp:licenceEu
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
|
- C[C@H]NC[C@@H]NC[C@@H]NC[C@@H]NC[C@@H]NC[C@@H]NCC (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N (en)
|
| dbp:synonyms
|
- Velcalcetide, telcalcetide, AMG-416, KAI-4169, ONO-5163 (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:url
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Etelcalcetid ist ein Arzneistoff zur Behandlung des sekundären Hyperparathyreoidismus, einer Erkrankung die vor allem bei Menschen mit einer Chronischen Nierenerkrankung auftritt und zu erhöhten Parathormon führt. (de)
- Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan. (en)
- L'ételcalcétide (ou velcacétide) est une molécule en cours de test comme médicament dans le traitement des hyperparathyroïdies secondaires. (fr)
|
| rdfs:label
|
- Etelcalcetid (de)
- Etelcalcetide (en)
- Ételcalcétide (fr)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
